ore holdings inc (ORXE:OTC US)
ore holdings inc (ORXE) Snapshot
|
Open
$0.14
|
Previous Close
$0.14
|
|
|
Day High
$0.14
|
Day Low
$0.14
|
|
|
52 Week High
06/21/12 - $0.34
|
52 Week Low
04/24/13 - $0.11
|
|
|
Market Cap
738.9K
|
Average Volume 10 Days
500.0
|
|
|
EPS TTM
$-0.71
|
Shares Outstanding
5.5M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
ore holdings inc (ORXE) Related Businessweek News
No Related Businessweek News Foundore holdings inc (ORXE) Details
Ore Holdings, Inc. focuses on developing and monetizing pharmaceutical assets, including clinical-stage compounds in-licensed from pharmaceutical companies. Its drug candidate portfolio includes ORE1001, an orally-administered small molecule drug for treating inflammatory bowel disease and other gastrointestinal indications; ORE10002, a small molecule serotonergic agent for inflammatory and autoimmune diseases; tiapamil, a small molecule L-type calcium channel antagonist to treat cardiovascular disease, various cognitive disorders, and gastrointestinal indications; and romazarit, a small molecule PPARá agonist for autoimmune, metabolic, inflammatory, and gastrointestinal diseases. The company was formerly known as Ore Pharmaceutical Holdings Inc. and changed its name to Ore Holdings, Inc. in June 2011. Ore Holdings, Inc. was founded in 1994 and is based in Cambridge, Massachusetts.
ore holdings inc (ORXE) Key Developments
Ore Holdings Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2011. For the quarter, the company reported loss from operations of $248,000 against $239,000 a year ago. Net loss was $353,000 or $0.04 per basic and diluted share against $237,000 or $0.04 per basic and diluted share a year ago. There was no revenue for the three month periods ended September 30, 2011 and September 30, 2010. For the nine months, the company reported loss from operations of $2,089,000 against $2,330,000 a year ago. Net loss was $2,432,000 or $0.28 per basic and diluted share against $2,307,000 or $0.42 per basic and diluted share a year ago. There was no revenue for the nine month periods ended September 30, 2011 and September 30, 2010.
Ore Holdings Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2011. For the quarter, the company reported net loss of $1,006,000 or $0.12 per basic and diluted share compared to net loss of $956,000 or $0.17 per basic and diluted share reported a year ago. Loss from operations was $893,000 compared to $968,000 for the same period of last year. For the six months, the company reported net loss of $2,078,000 or $0.24 per basic and diluted share compared to net loss of $2,070,000 or $0.38 per basic and diluted share reported a year ago. Loss from operations was $1,840,000 compared to $2,091,000 for the same period of last year.
Effective July 13, 2011, Ore Holdings, Inc will change its OTCPK stock ticker symbol to ORXE from ORXE.D.
| Recently Viewed | |||
| ORXE:US | $0.14 USD | 0.00 | |
| Company | Last | Change | |
| No competitor information is available for ORXE. | |||
| View Industry Companies | |||
Industry Analysis
ORXE
Industry Average
| Valuation | ORXE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact ORE HOLDINGS INC, please visit www.orepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.








